Phase 2
DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.
Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.
The immuno-oncology therapy, CAR-T, utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged, and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.
The National Institutes of Health ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.
The company plans to present detailed study results from the WILLOW study at an upcoming medical meeting.
United Therapeutics announced that its Phase II/III DISTINCT trial failed to meet its primary efficacy endpoint.
No treatments are currently approved for the disease.
Pharma companies from across the globe provide updates on their pipelines and business.
PRESS RELEASES